Panagora Asset Management Inc. Raises Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Panagora Asset Management increased its Bristol Myers Squibb stake by 11.7% in the fourth quarter, adding 345,009 shares and bringing its total position to 3.3 million shares worth about $177.8 million.
• Other major institutional investors, including Vanguard, State Street, Geode Capital, and Norges Bank, also boosted or initiated positions, and institutions now own about 76.41% of Bristol Myers Squibb’s stock.
• Bristol Myers Squibb recently beat quarterly earnings and revenue estimates, while analysts remain mixed with a consensus rating of Hold and a price target of $61.31.

Panagora Asset Management Inc. grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,295,820 shares of the biopharmaceutical company's stock after buying an additional 345,009 shares during the quarter. Bristol Myers Squibb accounts for 0.6% of Panagora Asset Management Inc.'s holdings, making the stock its 25th largest holding. Panagora Asset Management Inc. owned about 0.16% of Bristol Myers Squibb worth $177,777,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BMY. Vanguard Group Inc. raised its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares in the last quarter. State Street Corp increased its position in Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock valued at $5,285,065,000 after purchasing an additional 1,385,206 shares during the period. Geode Capital Management LLC increased its position in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $1,947,272,000. Finally, Primecap Management Co. CA lifted its position in shares of Bristol Myers Squibb by 12.6% in the 4th quarter. Primecap Management Co. CA now owns 24,875,550 shares of the biopharmaceutical company's stock worth $1,341,787,000 after purchasing an additional 2,781,230 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.05 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The business's fifty day simple moving average is $57.73 and its 200-day simple moving average is $56.94. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market cap of $116.49 billion, a PE ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts' expectations of $10.93 billion. During the same quarter last year, the firm earned $1.80 EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Barclays began coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an "overweight" rating and a $75.00 target price on the stock. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $61.31.

Insiders Place Their Bets

In other news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.